Drugs
Advances in diabetes research have been reported in three new studies from Japan, Taiwan, and the United States, providing insights into more effective treatments for type 1 diabetes mellitus and autonomic neuropathy. Researchers in Japan analyzed clinical data from 18,470 diabetic patients and found that intensive conventional insulin treatment
Drugs
Ajinomoto Co., Inc. and Sankyo Co., Ltd., both based in Tokyo, Japan, have entered into an agreement granting Sankyo exclusive global rights to develop, manufacture, and market the new diabetes drug AJD101 and related compounds. The collaboration marks the second partnership between the two companies, following their successful collaboration on
Pharmaceutical industry
Sequenom, a biomedical company, has appointed Paul W. Hawran to its board of directors, where he will chair the audit committee. Hawran brings a wealth of experience in financial leadership, having joined Neurocrine Biosciences as vice president and chief financial officer in 1993 and later serving as executive vice president
Pharmaceutical industry
Cancer Research Technology (CRT), a leading development and commercialization company focused on oncology, has entered into a significant agreement with AstraZeneca to advance research in colorectal cancer. This collaboration between CRT, the Cancer and Immunogenetics Laboratory led by Sir Walter Bodmer, and AstraZeneca aims to characterize the expression of key
Drugs
Researchers in the Netherlands, Japan, and the United Kingdom have made significant advancements in the treatment of small cell lung cancer (SCLC). Their studies have explored the efficacy of third-line chemotherapy, weekly chemotherapy with paclitaxel and carboplatin, and the impact of platinum-based treatment on survival rates in elderly patients. These
Drugs
Combined estrogen and testosterone therapy significantly increases the risk of invasive breast cancer in women, according to a study published in the Archives of Internal Medicine. Researchers at Harvard University analyzed data from the Nurses' Health Study, a prospective cohort study involving postmenopausal women. Over a 24-year period, 4,
Drugs
Researchers from the University States, Japan, and Cuba have made significant contributions to the field of cancer treatment in recent years. While there have been advances in various areas, there are still many challenges that need to be addressed in the development of effective cancer therapies. A key finding from
Drugs
Recent studies from the United States, Canada, and Japan have made significant strides in cancer research, focusing on adenovirus-based gene therapy and its applications in treating various types of cancer. Researchers have explored the use of chimeric oncolytic adenoviruses to enhance gene transfer and oncolysis of head and neck cancer
Pharmaceutical industry
CuraGen Corporation and TopoTarget A/S have initiated a Phase I clinical trial to evaluate the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine for the treatment of advanced hematologic malignancies. The trial is sponsored by the National Cancer Institute under a
Pharmaceutical industry
Vernalis plc, a leading pharmaceutical company, has initiated a phase 2a trial of its novel drug candidate, V3381, in patients with neuropathic pain caused by long-standing diabetes. This significant development marks a crucial step forward in the company's efforts to address a debilitating condition that affects millions worldwide.
Drugs
Recent research in the fields of immunology and oncology has led to the development of new cancer therapies in Australia, Taiwan, and Italy. In a study published in the Journal of Immunology, researchers from the Peter MacCallum Cancer Center in Melbourne, Australia, demonstrated that the combination of anti-DR5 antibody therapy
Drugs
Roche, a leading global healthcare company, received a negative opinion from the European Committee for Medicinal Products for Human Use regarding the approval of Tarceva (erlotinib) in combination with gemcitabine chemotherapy as first-line, once-daily, oral therapy for locally advanced, inoperable or metastatic pancreatic cancer. This decision is a setback for
